Tony Su, MD
Pulmonary Disease · Arlington, TXNPI 1366437865
Payments from drug & device makers
Across 335 payments — averaging $47.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Medtronic$2K
- GSK$2K
- ZOLL Respicardia, Inc.$2K
- AstraZeneca$1K
- Insmed, Inc.$512
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$1,72011%
- Travel & lodging$3,02519%
- Food & beverage$6,81942%
- Education$4,50028%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 20 | $6,431 |
| Medtronic | 26 | $2,279 |
| GSK | 98 | $1,843 |
| ZOLL Respicardia, Inc. | 2 | $1,649 |
| AstraZeneca | 52 | $1,118 |
| Insmed, Inc. | 34 | $512 |
| Inspire Medical Systems, Inc. | 9 | $365 |
| Boehringer Ingelheim | 16 | $328 |
| Mylan Specialty L.p. | 12 | $219 |
| Verona Pharma, Inc. | 9 | $200 |
| Baxter Healthcare | 8 | $146 |
| Regeneron Healthcare Solutions, Inc. | 7 | $137 |
| Grifols USA, LLC | 6 | $116 |
| Novartis | 6 | $104 |
| Johnson & Johnson | 1 | $97 |
| Amgen | 5 | $92 |
| Sanofi | 3 | $87 |
| Philips North America LLC | 5 | $83 |
| Inogen, Inc. | 4 | $57 |
| Electromed, Inc. | 5 | $55 |
| Viatris Specialty LLC | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Body Vision Medical Inc. | 1 | $21 |
| Merck | 1 | $20 |
| Shionogi Inc | 1 | $18 |
| Pinnacle Biologics, Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,948
- remede System$1,649
- AREXVY$240
- Inspire$145
- TEZSPIRE$116
- DA VINCI SP$103
How this compares
$16,064 in reported general payments places this provider in the 80th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 247 | $215,285 |
| TracleerBosentan | 12 | $136,883 |
| Spiriva RespimatTiotropium Bromide | 144 | $97,974 |
| TezspireTezepelumab-Ekko | 12 | $73,423 |
| SymbicortBudesonide/Formoterol Fumarate | 81 | $28,873 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 43 | $24,540 |
| Breo ElliptaFluticasone/Vilanterol | 48 | $23,940 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $22,136 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $21,560 |
| Incruse ElliptaUmeclidinium Bromide | 44 | $20,403 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 301 | $8,509 |
| Wixela InhubFluticasone Propion/Salmeterol | 67 | $7,663 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $7,047 |
| BreynaBudesonide/Formoterol Fumarate | 22 | $3,715 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $2,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,843 | $284,168382 claims |
| Actelion Pharmaceuticals US, Inc.Tracleer | $23 | $136,88312 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $1,118 | $124,433115 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $328 | $119,534172 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Arlington
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.